The idolatry of the surrogate

Easier to measure surrogate outcomes are often used instead of patient important outcomes such as death, quality of life, or functional capacity when assessing treatments. John Yudkin, Kasia Lipska, and Victor Montori argue that our obsession with surrogates is damaging patient care

[1]  M. Özkaya,et al.  Action to Control Cardiovascular Risk in Diabetes , 2013 .

[2]  B. Hemmingsen Targeting intensive glycaemic control versus targeting conventional glycaemic control for type 2 diabetes mellitus , 2011, The Cochrane database of systematic reviews.

[3]  Russell E. Glasgow,et al.  Diabetes Performance Measures: Current Status and Future Directions , 2011, Diabetes Care.

[4]  M. Mauer,et al.  Olmesartan, microalbuminuria, and type 2 diabetes. , 2011, The New England journal of medicine.

[5]  J. Yudkin,et al.  Intensified glucose control in type 2 diabetes—whose agenda? , 2011, The Lancet.

[6]  Roberta McKean-Cowdin,et al.  Severity of diabetic retinopathy and health-related quality of life: the Los Angeles Latino Eye Study. , 2011, Ophthalmology.

[7]  L. Ruilope,et al.  Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes. , 2011, The New England journal of medicine.

[8]  B. Krämer,et al.  Olmesartan, microalbuminuria, and type 2 diabetes. , 2011, The New England journal of medicine.

[9]  Harlan M Krumholz,et al.  Responding to an FDA warning--geographic variation in the use of rosiglitazone. , 2010, The New England journal of medicine.

[10]  H. Krumholz,et al.  Licensing drugs for diabetes , 2010, BMJ : British Medical Journal.

[11]  Rodica Pop-Busui,et al.  Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial , 2010, The Lancet.

[12]  J. Yudkin,et al.  Intensified glucose lowering in type 2 diabetes: time for a reappraisal , 2010, Diabetologia.

[13]  Walter T Ambrosius,et al.  Effects of medical therapies on retinopathy progression in type 2 diabetes. , 2010, The New England journal of medicine.

[14]  Justin W Timbie,et al.  Variation in the net benefit of aggressive cardiovascular risk factor control across the US population of patients with diabetes mellitus. , 2010, Archives of internal medicine.

[15]  Christine M. Micheel,et al.  Evaluation of Biomarkers and Surrogate Endpoints in Chronic Disease , 2010 .

[16]  J. Danesh,et al.  C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis , 2010, The Lancet.

[17]  Nick Freemantle,et al.  Effect of the quality and outcomes framework on diabetes care in the United Kingdom: retrospective cohort study , 2009, BMJ : British Medical Journal.

[18]  N J Wald,et al.  Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies , 2009, BMJ : British Medical Journal.

[19]  Michael E. Miller,et al.  Effects of intensive glucose lowering in type 2 diabetes. , 2008, The New England journal of medicine.

[20]  M. Caulfield,et al.  Effects of torcetrapib in patients at high risk for coronary events. , 2007, The New England journal of medicine.

[21]  S. Nissen,et al.  Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. , 2007, The New England journal of medicine.

[22]  Gordon H Guyatt,et al.  Problems with use of composite end points in cardiovascular trials: systematic review of randomised controlled trials , 2007, BMJ : British Medical Journal.

[23]  J. Diaz Albuminuria and Risk of Cardiovascular Events, Death, and Heart Failure in Diabetic and Nondiabetic Individuals , 2002 .

[24]  S. Yusuf,et al.  Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. , 2001, JAMA.

[25]  Bruce H. R. Wolffenbuttel,et al.  Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy , 2000, The Lancet.

[26]  S. Yusuf,et al.  Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators. , 2000 .

[27]  N. Chaturvedi,et al.  Developing risk stratification charts for diabetic and nondiabetic subjects , 1999, Diabetic medicine : a journal of the British Diabetic Association.

[28]  R. Holman,et al.  Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. , 1998 .

[29]  Uk-Prospective-Diabetes-Study-Group Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) , 1998, The Lancet.

[30]  S. Genuth,et al.  The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. , 1993, The New England journal of medicine.

[31]  Fundus photographic risk factors for progression of diabetic retinopathy. ETDRS report number 12. Early Treatment Diabetic Retinopathy Study Research Group. , 1991, Ophthalmology.